Basic Information
| LncRNA/CircRNA Name | NCK1-AS1 |
| Synonyms | NCK1 antisense RNA 1 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | RT-qPCR, Western blotting |
| Sample | fasting blood,PC cell lines, DU145 and 22Rv1, and a normal prostate cell line, RWPE-1 |
| Expression Pattern | up-regulated |
| Function Description | lasma NCK1-AS1 was upregulated in patients with PC.Upregulation of NCK1-AS1 distinguished patients with PC from patients with BPH and healthy controls. Overexpression of NCK1-AS1 led to significantly upregulated transforming growth factor (TGF)-?1, while TGF-?1 overexpression failed to significantly affect NCK1-AS1 in PC cells. NCK1-AS1 overexpression led to promoted migration and invasion. |
| Pubmed ID | 31807161 |
| Year | 2019 |
| Title | Altered Expression of lncRNA NCK1-AS1 Distinguished Patients With Prostate Cancer From Those With Benign Prostatic Hyperplasia |
External Links
| Links for NCK1-AS1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |